The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells

American Journal of Cancer Research

Volumn 7, Issue 5, 2017, Pages 1227-1237

  Huang, Tse Hung ^a,b,c   Wu, Szu Yuan ^d,e   Huang, Yan Jiun ^f,g,h   Wei, Po Li ^f,g   Wu, Alexander T H ^g,j   Chao, Tsu Yi ^g,i  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY   (Taiwan)

ⁱ TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^j NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

more..

Author keywords

5 FU resistance; Cancer stem like cells; Colon cancer; Drug resistance; Side population cells; Trichostatin A (TSA)

Indexed keywords

BETA CATENIN; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PROTEIN KINASE B; TRICHOSTATIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CANCER STEM LIKE CELL; CELL FUNCTION; CELL VIABILITY; COLON CANCER; COLON CANCER CELL LINE; CONTROLLED STUDY; DLD-1 CELL LINE; DRUG POTENTIATION; HCT 116 CELL LINE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SW480 CELL LINE; SW620 CELL LINE; VALIDATION PROCESS;

EID: 85019901203     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Boyle P and Langman JS. ABC of colorectal cancer: epidemiology. BMJ 2000; 321: 805-808
2. Haggar FA and Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22: 191-197
3. Calvert PM and Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002; 137: 603-612
4. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790
5. Dotse E and Bian Y. Isolation of colorectal cancer stem-like cells. Cytotechnology 2014; 23: 23
6. Zhan HX, Xu JW, Wu D, Zhang TP and Hu SY. Pancreatic cancer stem cells: new insight into a stubborn disease. Cancer Lett 2015; 357: 429-437
7. Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, Cruceru ML and Albulescu R. Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. World J Gastroenterol 2014; 20: 10790-10801
8. Damaskos C, Valsami S, Kontos M, Spartalis E, Kalampokas T, Kalampokas E, Athanasiou A, Moris D, Daskalopoulou A, Davakis S, Tsourouflis G, Kontzoglou K, Perrea D, Nikiteas N and Dimitroulis D. Histone deacetylase inhibitors: An attractive therapeutic strategy against breast cancer. Anticancer Res 2017; 37: 35-46
9. Samanta S, Rajasingh S, Cao T, Dawn B and Rajasingh J. Epigenetic dysfunctional diseases and therapy for infection and inflammation. Biochim Biophys Acta 2017; 1863: 518-528
10. Walkinshaw DR and Yang XJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 2008; 15: 237-243
11. Singh BN, Zhou H, Li J, Tipton T, Wang B, Shao G, Gilbert EN, Li Q and Jiang SW. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol 2011; 7: 1415-1428
12. Lo PK, Kanojia D, Liu X, Singh UP, Berger FG, Wang Q and Chen H. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene 2012; 31: 2614-2626
13. Lamb J. The connectivity map: a new tool for biomedical research. Nat Rev Cancer 2007; 7: 54-60
14. Carethers JM and Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 2015; 149: 1177-1190, e1173
15. Temraz S, Mukherji D and Shamseddine A. Dual inhibition of MEK and PI3K pathway in KRAS and BRAF mutated colorectal cancers. Int J Mol Sci 2015; 16: 22976-22988
16. Waring P, Tie J, Maru D and Karapetis CS. RAS mutations as predictive biomarkers in clinical management of metastatic colorectal cancer. Clin Colorectal Cancer 2016; 15: 95-103
17. Dannenberg LO and Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 2006; 7: 181-181
18. Stoian M, Stoica V and Radulian G. Stem cells and colorectal carcinogenesis. J Med Life 2016; 9: 6-11
19. Mathew G, Timm EA Jr, Sotomayor P, Godoy A, Montecinos VP, Smith GJ and Huss WJ. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle 2009; 8: 1053-1061
20. Petriz J. Flow cytometry of the side population (SP). Curr Protoc Cytom 2013; 9: Unit9.23
21. Davies JM, Santaolalla R and Abreu MT. Use of cancer stem cells to investigate the pathogenesis of colitis-associated cancer. Inflamm Bowel Dis 2016; 22: 976-983
22. Han Y, Xue X, Jiang M, Guo X, Li P, Liu F, Yuan B, Shen Y, Guo X, Zhi Q and Zhao H. LGR5, a relevant marker of cancer stem cells, indicates a poor prognosis in colorectal cancer patients: a meta-analysis. Clin Res Hepatol Gastroenterol 2015; 39: 267-273
23. Lin YU, Wu T, Yao Q, Zi S, Cui L, Yang M and Li J. LGR5 promotes the proliferation of colorectal cancer cells via the Wnt/beta-catenin signaling pathway. Oncol Lett 2015; 9: 2859-2863
24. Osawa H, Takahashi H, Nishimura J, Ohta K, Haraguchi N, Hata T, Yamamoto H, Mizushima T, Takemasa I, Doki Y and Mori M. Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer. Br J Cancer 2016; 114: 1251-1260
25. Pan Q, Meng L, Ye J, Wei X, Shang Y, Tian Y, He Y, Peng Z, Chen L, Chen W, Bian X and Wang R. Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT). Cancer Lett 2017; 392: 26-38
26. Paschall AV, Yang D, Lu C, Redd PS, Choi JH, Heaton CM, Lee JR, Nayak-Kapoor A and Liu K. CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype. Oncotarget 2016; 7: 78698-78712
27. Le Rolle AF, Chiu TK, Zeng Z, Shia J, Weiser MR, Paty PB and Chiu VK. Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. Oncotarget 2016; 7: 2159-2174
28. Zhong X, Zheng L, Shen J, Zhang D, Xiong M, Zhang Y, He X, Tanyi JL, Yang F, Montone KT, Chen X, Xu C, Xiang AP, Huang Q, Xu X and Zhang L. Suppression of MicroRNA 200 family expression by oncogenic KRAS activation promotes cell survival and epithelial-mesenchymal transition in KRAS-driven cancer. Mol Cell Biol 2016; 36: 2742-2754
29. Hong S, Kim S, Kim HY, Kang M, Jang HH and Lee WS. Targeting the PI3K signaling pathway in KRAS mutant colon cancer. Cancer Med 2016; 5: 248-255
30. Wang Q, Tan R, Zhu X, Zhang Y, Tan Z, Su B and Li Y. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression. Oncotarget 2016; 7: 10064-10072
31. Song N, Jia XS, Jia LL, Ma XB, Li F, Wang EH and Li X. Expression and role of Oct3/4, Nanog and Sox2 in regeneration of rat tracheal epithelium. Cell Prolif 2010; 43: 49-55
32. Kobayashi S, Yamada-Okabe H, Suzuki M, Natori O, Kato A, Matsubara K, Jau Chen Y, Yamazaki M, Funahashi S, Yoshida K, Hashimoto E, Watanabe Y, Mutoh H, Ashihara M, Kato C, Watanabe T, Yoshikubo T, Tamaoki N, Ochiya T, Kuroda M, Levine AJ and Yamazaki T. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 2012; 30: 2631-2644
33. Chen J, Shao R, Li F, Monteiro M, Liu JP, Xu ZP and Gu W. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. Clin Exp Pharmacol Physiol 2015; 42: 1317-1326
34. Erdogan S, Doganlar O, Doganlar ZB, Serttas R, Turkekul K, Dibirdik I and Bilir A. The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-kappaB signaling. Life Sci 2016; 162: 77-86
35. Ayinde O, Wang Z and Griffin M. Tissue transglutaminase induces epithelial-mesenchymal-transition and the acquisition of stem cell like characteristics in colorectal cancer cells. Oncotarget 2017; 8: 20025-20041
36. Offer SM and Diasio RB. Biomarkers of fluorouracil toxicity: insight from the PETACC-8 trial. JAMA Oncol 2016; [Epub ahead of print]
37. Saif MW and Diasio RB. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. Cancer Chemother Pharmacol 2016; 78: 151-156